ALAMEDA, Calif., Oct. 14 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN), maker of advanced imaging systems designed to accelerate drug
discovery and development, today announced that Michael J. Sterns, Vice
President and Chief Business Officer, will present at the 2005 BIO Investor
Forum to be held October 19 - 20 at the Palace Hotel in San Francisco.
Xenogen's presentation will take place at 9:40 a.m. Pacific Time on
Thursday, October 20, 2005. There will be a live audio webcast of the
presentation, which will be accessible through a link posted on the investor
relations section of Xenogen's website at http://www.xenogen.com. The webcast will
be available for replay on Xenogen's website for two weeks through November 3,
2005.
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology is designed to provide high quality in vivo data
earlier in the drug discovery and development process. VivoVision(TM)
Solutions are designed to improve discovery and pre-clinical research in
multiple therapeutic areas. VivoVision(TM) Biosciences represents more than
15 years of experience in the creation and characterization of animal models,
including genetic modifications, comprehensive phenotyping, compound profiling
and custom design and production of light producing cells, microorganisms and
animals.
More information is available at http://www.xenogen.com. Xenogen(R), Living
Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
William A. Albright, Chief Financial Officer
of Xenogen Corporation, +1-510-291-6100
|
